Collectionner le produit
Détails du produit
Synonyms
FIGF, VEGFD
Source
Mouse VEGF-D Protein, Fc Tag (VED-M5253) is expressed from human 293 cells (HEK293). It contains AA Phe 98 - Ser 206 (Accession # P97946).
Predicted N-terminus: Phe 98
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 39.3 kDa. The protein migrates as 45-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Mouse VEGF-D Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Mouse VEGF R3 Protein, Mouse IgG2a Fc Tag (Cat. No. FL4-M5251) at 5 μg/mL (100 μL/well) can bind Mouse VEGF-D Protein, Fc Tag (Cat. No. VED-M5253) with a linear range of 0.3-20 ng/mL (QC tested).
Protocol
Bioactivity-SPR
Mouse VEGF-D Protein, Fc Tag (Cat. No. VED-M5253) captured on CM5 chip via anti-Human IgG Fc antibody, can bind Mouse VEGF R3 Protein, Mouse IgG2a Fc Tag (Cat. No. FL4-M5251) with an affinity constant of 6.69 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Vascular endothelial growth factor D
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
2 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
